Adalimumab increased interval in CD
LAG-3 depleting antibody GSK2831781 in UC
Phase 2 trial, guselkumab in Crohn’s disease efficacy and safety at week 48
Vedolizumab, adalimumab and methotrexate combination in CD
Etrasimod in UC
Vedolizumab in chronic pouchitis
Filgotinib in small bowel Crohn’s disease
Curcumin and QingDai for induction of remission in UC
Methotrexate combination pediatric CD
Beta-fructan fibers impact in IBD